A group led by Sarah Ringold, MD, MS, assistant professor of rheumatology at Seattle Children’s Hospital, has developed a new guideline intended to provide recommendations for the treatment and monitoring of children with juvenile idiopathic arthritis (JIA) manifesting as non-systemic polyarthritis, sacroiliitis or enthesitis.1,2 Key Updates The new recommendations appear in both Arthritis & Rheumatology…
Search results for: pediatric
FDA Approves Drug for Lambert-Eaton Myasthenic Syndrome
(Reuters)—Jacobus Pharmaceutical Co Inc on Monday won U.S. approval for the first drug to treat children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder. The drug, Ruzurgi (amifampridine), was approved for use in patients ages 6–17, the according to the U.S. Food and Drug Administration (FDA). Lambert-Eaton myasthenic syndrome (LEMS), which affects about three people…
New Guideline Recommends Frequent Monitoring & Collaboration for JIA-Associated Uveitis Management
As soon as pediatric patients are diagnosed with juvenile idiopathic arthritis (JIA), they should also be screened for uveitis, says ophthalmologist Gary Holland, MD. Otherwise, the University of California, Los Angeles, provider says, “Kids who are diagnosed with JIA may not come to an ophthalmologist until they have vision-limiting complications.” Uveitis is the most common…
ACR Leaders to Meet with Members of Congress
On May 16, ACR and ARP leaders serving on the Board of Directors, Affiliate Society Council, Government Affairs Committee, Committee on Rheumatologic Care, RheumPAC and Insurance Subcommittee will go to Capitol Hill to advocate on behalf of the College’s membership and our patients. The group represents 31 states and the District of Columbia, and will…
Parent-Child Reminiscing Affects Children’s Pain Memories
NEW YORK (Reuters Health)—How parents and children reminisce about the child’s recent surgery affects the child’s pain memory, researchers from Canada report. Children who recall pain that is higher than initially reported are more likely to report more pain and distress during future pain experiences. These negatively biased memories, formed early in life, set the…
Why Fellows Should Care about ACR Advocacy
As a physician, I am an advocate. I am an advocate for my patients individually and collectively, and I am an advocate for my field: pediatric rheumatology. My own experiences as a patient drive me to integrate my patients’ perspectives into my medical decision making, and although my academic training has prepared me to best…
New Tools for Myositis Diagnosis, Classification & Management
CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…
Did Shiitake Mushrooms Induce Immune-Mediated Necrotizing Myopathy?
Idiopathic inflammatory myopathies are heterogenous, acquired immune-mediated muscle diseases. Over the past decade, immune-mediated necrotizing myopathy has been recognized as a subcategory of idiopathic inflammatory myopathy characterized by myofiber necrosis in the absence of prominent inflammatory cells.1 Autoantibodies against signal recognition particle (SRP) and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) are thought to be associated with the…
The ACR Supports Its Members Via Collaboration
We all know words can be powerful. They often resonate with several levels of meaning, enriching our understanding and broadening our perspective. Take the word promise, for example. It implies responsibility, as in, “We promise to do it.” It is also imbued with hope, as in “This idea has great promise.” At the ACR we…
Disease Mimicry: Genetic Diseases Can Produce Rheumatic Symptoms
CHICAGO—The 2018 ACR/ARHP Annual Meeting session on genetic mimics of rheumatic disease began with a description of a patient who presented with the symptoms of childhood-onset lupus but instead had a well-defined genetic disease: lysinuric protein intolerance (LPI). Lindsay Burrage, MD, PhD, assistant professor of molecular and human genetics at Baylor College of Medicine, Houston,…
- « Previous Page
- 1
- …
- 52
- 53
- 54
- 55
- 56
- …
- 109
- Next Page »